# US 2012/0270322 A1 · Shuttle vectors for mycobacteria-escherichia coli and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0270322 A1
- Document ID: US20120270322A1
- Status: Published application
- Kind: A1
- Application number: 13/450,689
- Filed: 2012-04-19
- Published: 2012-10-25
- Earliest claimed: 2011-04-21
- Assignees: Snu R&Db Foundation
- Inventors: Bum-Joon KIM; Hyungki LEE
- Web page: https://patentgrep.com/patent/US20120270322A1

## CPC

- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a DNA molecule capable of replication in Mycobacteria having a nucleic acid sequence as disclosed in SEQ ID NO: 1, a shuttle vector constructed using it and a transformed cells containing the present vector. The vector of about 18 kb of the present disclosure contains 16 ORFs, a replication origin and a rep-like protein essential for replication. Therefore, the plasmid of the present disclosure can be utilized as a gene delivery system/research, and also in a therapeutic system such as immune therapeutics by effectively delivering proteins or heterologous DNA and expressing the encoded DNA in cells.

## Claims

### Claim 1

A DNA molecule capable of replication in a mycobacterium having a nucleic acid sequence as disclosed in SEQ ID NO: 1.

### Claim 2

A Mycobacteria-Escherichia coli shuttle vector comprising:
(a) an origin of replication having a nucleic acid sequence as disclosed in SEQ ID NO: 2 (oriM);
(b) an origin of replication for prokaryotic cells;
(c) a promoter; and
(d) a transgene, which is operatively linked to the promoter.

### Claim 3 (depends on 2)

The shuttle vector according to claim 2, wherein the nucleic acid sequence of ori M contains A+T rich region and direct repeat region.

### Claim 4 (depends on 2)

The shuttle vector according to claim 2, wherein the promoter includes a heat shock protein promoter, a CMV promoter, a promoter for 65 kDa common antigen of mycobacteria, ribosome RNA promoter from Mycobacteria, a promoter for MPB77, MPB59 or MPB64 antigen from Mycobacterium bovis, P1 promoter from bacteriophage Lamda, tac promoter, trp promoter, lac promoter, lacUV5 promoter, Ipp promoter, PAλ promoter, PRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, T7 promoter, a promoter for kanamycin resistance gene of transposon Tn903 or Tn5, a promoter for metallothionine, a promoter for growth hormone or a hybrid promoter between an eukaryotic and a prokaryotic promoter, or a combination thereof.

### Claim 5 (depends on 2)

The shuttle vector according to claim 2, wherein the transgene encodes a protein, antisense oligonucleotide, siRNA, shRNA, miRNA or piRNA.

### Claim 6 (depends on 5)

The shuttle vector according to claim 5, wherein the protein is a reporter protein, an antigen or a therapeutic protein.

### Claim 7 (depends on 6)

The shuttle vector according to claim 6, wherein the protein is a reporter protein which includes fluorescent protein, beta-galactosidase, chloramphenicol acetyl transferase, human growth hormone, urease or alkaline phosphatase.

### Claim 8 (depends on 7)

The shuttle vector according to claim 7, wherein the fluorescent protein includes GFP (green fluorescent protein), RFP (red fluorescent protein), CFP (cyan fluorescent protein), YFP (yellow fluorescent protein), BFP (blue fluorescent protein) or its variants.

### Claim 9 (depends on 6)

The shuttle vector according to claim 6, wherein the antigen is an antigen derived from virujent pathogens.

### Claim 10 (depends on 9)

The shuttle vector according to claim 9, wherein the antigen includes hepatitis B virus (HBV) surface antigen, HBV core antigen, human immune-deficiency (HIV) gag protein and Mycobacterium tuberculosis Antigen 85A.

### Claim 11 (depends on 6)

The shuttle vector according to claim 6, wherein the therapeutic protein includes IL-12 or GM-CSF.

### Claim 12 (depends on 2)

The shuttle vector according to claim 2, wherein the vector further includes one or more selective markers.

### Claim 13 (depends on 8)

The shuttle vector according to claim 8, wherein the markers include genes conferring resistance to antibiotics which include kanamycin, hygromycin, ampicillin, streptomycin, penicillin, chloramphenicol, gentamicin, carbenicillin, geneticin, neomycin or tetracycline.

### Claim 14 (depends on 2)

The shuttle vector according to claim 2, wherein the vector can be co-transformed with an expression vector having an origin of replication other than the oriM.

### Claim 15 (depends on 2)

A cell transformed with the vector according to claim 2.

### Claim 16 (depends on 11)

The cell according to claim 11, wherein the cell is Mycobacteria or Escherichia coli.

### Claim 17 (depends on 12)

The cell according to claim 12, wherein the Mycobacteria includes M. smegmatis, M. bovis-BCG, M. avium, M. phlei, M. fortuitum, M. lufu, M. partuberculosis, M. habana, M. scrofulaceum, or M. intracellulare.

### Claim 18 (depends on 1)

A method of using a first and a second vector for expression of heterologous transgenes in a eukaryotic cell, wherein the first vector is the vector according to claim 1 and the second vector is pSE100 and its derivatives in eukaryotic cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein the transgene encodes a protein, antisense oligonucleotide, siRNA, shRNA, miRNA or piRNA, and the transgene encoded by the first and the second vector is different.

### Claim 20 (depends on 19)

The method of claim 19, wherein the protein is a reporter protein, an antigen or a therapeutic protein.

### Claim 21 (depends on 20)

The method of claim 20, wherein the reporter protein includes fluorescent protein, beta-galactosidase, chloramphenicol acetyl transferase, human growth hormone, urease or alkaline phosphatase; wherein the antigen is derived from virulent pathogens; and wherein the therapeutic protein includes IL-12 or GM-CSF.
